NCT02047539

Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis

Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Patients With the Clinical Risk Syndrome for Psychosis

• Status: Terminated
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 19 Years – 35 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to determine whether aspirin is effective in alleviating symptoms of the clinical high risk (CHR) syndrome for psychosis. The investigators further aim to determine whether it may delay or prevent the onset of psychosis in those currently experiencing CHR symptoms. As secondary measures the investigators aim to collect laboratory studies of inflammation markers and genetic samples to determine whether certain genetic profiles correlate with risk for psychosis, or response to aspirin treatment.

Detailed description

Patients will be randomly assigned to either active treatment (aspirin) or placebo.

Conditions

• Clinical High Risk for Psychosis

Interventions

Type	Name	Description
DRUG	Aspirin	1000 mg/day of aspirin 1000 mg/day of sugar pill
DRUG	Placebo

Timeline

• Start date: 2015-01-01
• Primary completion: 2021-03-01
• Completion: 2021-03-01
• First posted: 2014-01-28
• Last updated: 2021-05-17

Locations

1 site across 1 country: United States